DMU-212|cas 134029-62-2|DC Chemicals

Cas No.:	134029-62-2
Chemical Name:	Benzene,1,2,3-trimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-
Synonyms:	Benzene,1,2,3-trimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-;1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene;1,2,3-trimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]Benzene;3,4,5,4'-TETRAMETHOXYSTILBENE;1,2,3-trimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]benzene;1,2,3-Trimethoxy-5-[(E)-2-(4-methoxyphenyl)vinyl]benzene;benzene, 1,2,3-trimethoxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]-;1,2,3-Trimethoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]-benzene;DMU 212;MR-4;(E)-1,2,3-Trimethoxy-5-[2-(4-methoxyphenyl)ethenyl]benzene;DMU-212
SMILES:	COC1C=C(/C=C/C2C=CC(OC)=CC=2)C=C(OC)C=1OC
Formula:	C₁₈H₂₀O₄
M.Wt:	300.349
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	DMU-212 is a methylated derivative of Resveratrol (HY-16561), with antimitotic, anti-proliferative, antioxidant and apoptosis promoting activities. DMU-212 induces mitotic arrest via induction of apoptosis and activation of ERK1/2 protein. DMU-212 has oral bioavailability[1][2].
In Vivo:	DMU-212 (50 mg/kg; i.g.; three times a week; for 14 days) inhibits tumor growth in xenograft model of human ovarian cancer[2]. Animal Model: 6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts[2] Dosage: 50 mg/kg Administration: Oral gavage, three times a week, for 14 days Result: Lower tumor burden.
In Vitro:	DMU-212 (0.3125-40 μM) inhibits growth of A375, MeWo, Bro and M5 cells human melanoma cells[1]. DMU-212 (30-50 μM; 24 hours) induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells[1]. DMU-212 induces upregulation of cell cycle inhibitors, apoptosis and ERK activation in A375 cells[1]. DMU-212 induces G2/M arrest and apoptosis in cancer cells[1]. DMU-212 induces mitotic arrest, apoptosis and activation of ERK1/2 protein[1]. Cell Proliferation Assay[1] Cell Line: A375 cells, MeWo cells, M5 cells, Bro cells Concentration: 0.3125 μM, 0,625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM Incubation Time: 96 hours Result: Inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC50=0.5 μM for A375 and Bro and IC50= 1.25 μM for MeWo and M5 cells). Cell Cycle Analysis[1] Cell Line: A375 cells Concentration: 20 μM, 30 μM, 50 μM Incubation Time: 24 hours Result: Caused a marked increase in the levels of p21, p53 and cyclin B1 proteins with a concomitant decrease in the levels of cyclin A2. Western Blot Analysis[1] Cell Line: A375 cells Concentration: 20 μM, 30 μM, 50 μM Incubation Time: 24 hours Result: Significant upregulation of Bax, caspase 3 and caspase 9 protein levels, while the levels of the anti-apoptotic protein Bcl-2 were decreased.
References:	[1]. Vasilis Pericles Androutsopoulos, et al. Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells. Exp Dermatol. 2015 Aug;24(8):632-4. [2]. Hanna Piotrowska, et al. DMU-212 inhibits tumor growth in xenograft model of human ovarian cancer. Biomed Pharmacother. 2014 May;68(4):397-400.

Cat. No.	Product name	Field of application
DC82301	IC-8	IC8 is an ionizable cationic lipid. It has been used in combination with other lipids for the formation of lipid nanoparticles (LNPs). Immunization with severe acute respiratory coronavirus 2 (SARS-CoV-2) spike glycoprotein mRNA in IC8- and manganese-containing LNPs induces IgG responses to SARS-CoV-2 Delta and Omicron variants in mice.1 Administration of mRNA encoding B7-H3 X CD3 bispecific T cell engaging (BiTE) antibodies in IC8-containing LNPs reduces tumor growth in MV4-11 and A375 mouse xenograft models.
DC75721	CL2A-SN38 (Govitecan)	CL2A-SN38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an antibody-drug conjugate (ADC). CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .
DC47877	tri-GalNAc-COOH (acetylation)	tri-GalNAc-COOH acetylation is the acetylated and modified form of tri-GalNAc-COOH. tri-GalNAc-COOH acetylation can be used for the synthesis of LYTAC.
DC46965	Tri-GalNAc-COOH	tri-GalNAc-COOH is an asialoglycoprotein receptor (ASGPR) ligand that can be used for LYsosome TArgeting Chimera (LYTAC) research.
DC46471	RP101988	RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely.
DC37901	PD-173212	PD-173212 is a small molecule N-type calcium channel blocker.
DC37333	N,N-Diethyl-p-toluamide	N,N-Diethyl-p-toluamide is a mosquito repellent.
DC37321	AI3-15902	AI3-15902 is a biochemical.
DC37283	Methyl phenylcarbamate	Methyl phenylcarbamate is a biochemical.
DC37252	Ampyrone	Ampyrone is a metabolite of AMINOPYRINE with analgesic and anti-inflammatory properties. It is used as a reagent for biochemical reactions producing peroxides or phenols. Ampyrone stimulates LIVER MICROSOMES and is also used to measure extracellular water.

DMU-212（resveratrol analog）